Waiting for answers on health care - Daily Comet

Waiting for answers on health care Daily Comet I asked her what the 15-member federal board, which was funded in the stimulus bill, will be for if not to oversee who gets what treatment based on ...

Voter Anger Is Building Over Deficits - Wall Street Journal

Los Angeles Times

Voter Anger Is Building Over Deficits Wall Street Journal However, since taking office Mr. Obama pushed through a $787 billion stimulus, a $33 billion expansion of the child health program known as S-chip, ... Jobs bill becomes a priority for Democrats Obama's Tattered Coattails

8 Health Stocks Poised to Gain in 2010 - TheStreet.com

8 Health Stocks Poised to Gain in 2010 TheStreet.com Significance of 2010: The stimulus package that was passed has lots of funding going to physicians to demonstrate "meaningful use" of electronic health ...

Virdante Pharmaceuticals, Inc.: Series A $30M

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

Quinnova Pharmaceuticals, Inc.: Series B $17.4M

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

Activaero, GmbH: Series A $15.9M

Activaero (Germany) a commercial-stage medical device company focused on patient-tailored controlled breathing and inhaled therapeutic delivery systems, closed a $15.9M Series A financing. Participants include BioMedPartners, VI Partners, Abalis Finance and Vesalius Biocapital.

3Q09 OnBioVC | Trend Analysis Now Available

Hot off the press! The 3Q09 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you [...]

September 2009 OnBioVC | Trend Analysis Now Available

Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]